{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T19:54:02Z","timestamp":1789329242908,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T00:00:00Z","timestamp":1716595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-02958-6","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T02:02:04Z","timestamp":1716602524000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Janus kinase inhibitors in the treatment of pyoderma gangrenosum: case report and review"],"prefix":"10.1007","volume":"316","author":[{"given":"Alison","family":"Gris\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn-Caelle","family":"Valere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,25]]},"reference":[{"issue":"4","key":"2958_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jamadermatol.2017.5978","volume":"1","author":"HJ Ashchyan","year":"2018","unstructured":"Ashchyan HJ, Butler DC, Nelson CA et al (2018) The Association of Age with Clinical Presentation and comorbidities of Pyoderma Gangrenosum. JAMA Dermatol Apr 1(4):409\u2013413. https:\/\/doi.org\/10.1001\/jamadermatol.2017.5978","journal-title":"JAMA Dermatol Apr"},{"issue":"8","key":"2958_CR2","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/ijd.16676","volume":"62","author":"LGM Castro","year":"2023","unstructured":"Castro LGM (2023) JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum. Int J Dermatol Aug 62(8):1088\u20131093. https:\/\/doi.org\/10.1111\/ijd.16676","journal-title":"Int J Dermatol Aug"},{"issue":"9","key":"2958_CR3","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.jdcr.2020.07.035","volume":"6","author":"AW Choi","year":"2020","unstructured":"Choi AW, Abuav R, Rabizadeh SM, Ansari R, Marsch AF (2020) Recalcitrant and severe pyoderma gangrenosum attributable to levamisole-adulterated cocaine and treated successfully with oral tofacitinib. JAAD Case Rep Sep 6(9):939\u2013941. https:\/\/doi.org\/10.1016\/j.jdcr.2020.07.035","journal-title":"JAAD Case Rep Sep"},{"issue":"4","key":"2958_CR4","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","volume":"148","author":"R Chovatiya","year":"2021","unstructured":"Chovatiya R, Paller AS (2021) JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol Oct 148(4):927\u2013940. https:\/\/doi.org\/10.1016\/j.jaci.2021.08.009","journal-title":"J Allergy Clin Immunol Oct"},{"issue":"3","key":"2958_CR5","first-page":"5","volume":"23","author":"A Cinats","year":"2018","unstructured":"Cinats A, Heck E, Robertson L (2018) Janus kinase inhibitors: a review of their emerging applications in Dermatology. Skin Therapy Lett May 23(3):5\u20139","journal-title":"Skin Therapy Lett May"},{"issue":"11","key":"2958_CR6","doi-asserted-by":"publisher","first-page":"e595","DOI":"10.1111\/ijd.16791","volume":"62","author":"MR Dos Santos","year":"2023","unstructured":"Dos Santos MR, Ianhez M, Ribeiro BN, de Queiroz BB, Miot HA (2023) Refractory pyoderma gangrenosum associated with rheumatoid arthritis successfully treated with upadacitinib. Comments on: JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum. Int J Dermatol Nov 62(11):e595\u2013e598. https:\/\/doi.org\/10.1111\/ijd.16791","journal-title":"Int J Dermatol Nov"},{"key":"2958_CR7","doi-asserted-by":"publisher","unstructured":"George C, Deroide F, Rustin M (May 2019) Pyoderma gangrenosum - a guide to diagnosis and management\u2002Clin Med (Lond). 19(3):224\u2013228. https:\/\/doi.org\/10.7861\/clinmedicine.19-3-224","DOI":"10.7861\/clinmedicine.19-3-224"},{"issue":"7","key":"2958_CR8","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1093\/ibd\/izz015","volume":"18","author":"MH Gregory","year":"2019","unstructured":"Gregory MH, Ciorba MA, Deepak P, Christophi GP (2019) Successful treatment of Pyoderma Gangrenosum with Concomitant Tofacitinib and Infliximab. Inflamm Bowel Dis Jun 18(7):e87\u2013e88. https:\/\/doi.org\/10.1093\/ibd\/izz015","journal-title":"Inflamm Bowel Dis Jun"},{"issue":"5","key":"2958_CR9","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.cgh.2018.10.047","volume":"17","author":"B Kochar","year":"2019","unstructured":"Kochar B, Herfarth N, Mamie C, Navarini AA, Scharl M, Herfarth HH (2019) Tofacitinib for the treatment of Pyoderma Gangrenosum. Clin Gastroenterol Hepatol Apr 17(5):991\u2013993. https:\/\/doi.org\/10.1016\/j.cgh.2018.10.047","journal-title":"Clin Gastroenterol Hepatol Apr"},{"issue":"1","key":"2958_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41572-020-0213-x","volume":"8","author":"E Maverakis","year":"2020","unstructured":"Maverakis E, Marzano AV, Le ST et al (2020) Pyoderma Gangrenosum. Nat Rev Dis Primers Oct 8(1):81. https:\/\/doi.org\/10.1038\/s41572-020-0213-x","journal-title":"Nat Rev Dis Primers Oct"},{"issue":"1","key":"2958_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","volume":"2","author":"IB McInnes","year":"2019","unstructured":"McInnes IB, Byers NL, Higgs RE et al (2019) Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther Aug 2(1):183. https:\/\/doi.org\/10.1186\/s13075-019-1964-1","journal-title":"Arthritis Res Ther Aug"},{"issue":"2","key":"2958_CR12","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/bjd.16468","volume":"179","author":"S Nasifoglu","year":"2018","unstructured":"Nasifoglu S, Heinrich B, Welzel J (2018) Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor. Br J Dermatol Aug 179(2):504\u2013505. https:\/\/doi.org\/10.1111\/bjd.16468","journal-title":"Br J Dermatol Aug"},{"issue":"6","key":"2958_CR13","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/ced.14683","volume":"46","author":"VE Orfaly","year":"2021","unstructured":"Orfaly VE, Kovalenko I, Tolkachjov SN, Ortega-Loayza AG, Nunley JR (2021) Tofacitinib for the treatment of refractory pyoderma gangrenosum. Clin Exp Dermatol Aug 46(6):1082\u20131085. https:\/\/doi.org\/10.1111\/ced.14683","journal-title":"Clin Exp Dermatol Aug"},{"issue":"10","key":"2958_CR14","doi-asserted-by":"publisher","first-page":"733","DOI":"10.17235\/reed.2021.7977\/2021","volume":"113","author":"P Salm\u00f3n Olavarr\u00eda","year":"2021","unstructured":"Salm\u00f3n Olavarr\u00eda P, Rubio Iturria S, Nantes Castillejo \u00d3 (2021) Tofacitinib, a useful option for the treatment of pyoderma gangrenosum in an ulcerative colitis patient. Rev Esp Enferm Dig Oct 113(10):733\u2013734. https:\/\/doi.org\/10.17235\/reed.2021.7977\/2021","journal-title":"Rev Esp Enferm Dig Oct"},{"key":"2958_CR15","doi-asserted-by":"publisher","unstructured":"Sasor SE, Soleimani T, Chu MW, Cook JA, Nicksic PJ, Tholpady SS (2018) Pyoderma gangrenosum demographics, treatments, and outcomes: an analysis of 2,273 cases. J Wound Care. Jan 1. ;27(Sup1):S4-s8. https:\/\/doi.org\/10.12968\/jowc.2018.27.Sup1.S4","DOI":"10.12968\/jowc.2018.27.Sup1.S4"},{"key":"2958_CR16","doi-asserted-by":"publisher","first-page":"100099","DOI":"10.1016\/j.jtauto.2021.100099","volume":"4","author":"M Scheinberg","year":"2021","unstructured":"Scheinberg M, Machado LA, LG MC, Ferreira SB, Michalany N (2021) Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor. J Transl Autoimmun 4:100099. https:\/\/doi.org\/10.1016\/j.jtauto.2021.100099","journal-title":"J Transl Autoimmun"},{"issue":"5","key":"2958_CR17","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1093\/ibd\/izab005","volume":"15","author":"R Sedano","year":"2021","unstructured":"Sedano R, Jairath V (2021) Tofacitinib for the treatment of three Immune-mediated conditions in one patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata. Inflamm Bowel Dis Apr 15(5):e65. https:\/\/doi.org\/10.1093\/ibd\/izab005","journal-title":"Inflamm Bowel Dis Apr"},{"issue":"6","key":"2958_CR18","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1053\/j.jfas.2013.07.003","volume":"52","author":"VK Shanmugam","year":"2013","unstructured":"Shanmugam VK, McNish S, Shara N et al (2013) Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi(\u00ae)). J Foot Ankle Surg. Nov-Dec 52(6):781\u2013785. https:\/\/doi.org\/10.1053\/j.jfas.2013.07.003","journal-title":"Nov-Dec"},{"key":"2958_CR19","doi-asserted-by":"publisher","unstructured":"Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM (2022) A comprehensive overview of globally approved JAK inhibitors. Pharm May 6(5). https:\/\/doi.org\/10.3390\/pharmaceutics14051001","DOI":"10.3390\/pharmaceutics14051001"},{"issue":"6","key":"2958_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1177\/0141076814534407","volume":"107","author":"A Teagle","year":"2014","unstructured":"Teagle A, Hargest R (2014) Management of pyoderma gangrenosum. J R Soc Med Jun 107(6):228\u2013236. https:\/\/doi.org\/10.1177\/0141076814534407","journal-title":"J R Soc Med Jun"},{"key":"2958_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1750-1172-2-19","volume":"15","author":"U Wollina","year":"2007","unstructured":"Wollina U (2007) Pyoderma gangrenosum\u2013a review. Orphanet J Rare Dis Apr 15:2:19. https:\/\/doi.org\/10.1186\/1750-1172-2-19","journal-title":"Orphanet J Rare Dis Apr"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-02958-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-02958-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-02958-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T07:32:12Z","timestamp":1719387132000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-02958-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,25]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["2958"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-02958-6","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,25]]},"assertion":[{"value":"19 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The participant has consented to the submission of the case report to the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent was obtained from the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"238"}}